Big pharma is not going to jump in and play sugar daddy any time soon. Are some of them keeping an eye out on NNVC? No doubt. But they won't be offering any money before phase 1 trials are even completed.
Only a very naive person believes government officials when they say that our debt problem is getting better. But that's another matter. The biggest risks for NNVC are not macroeconomic but the usual ones for a start up drug development company.
News 
Market Data 
Discover 
AI
